How CFOs Can Control Self-Funded Pharmacy Costs
Pharmacy costs are rising faster than many other components of employer health spending. For self-funded groups, these increases are even more difficult to ignore because every dollar of pharmacy utilization flows directly onto the company’s balance sheet. Specialty drugs, high-cost chronic disease management, and opaque PBM pricing structures are putting sustained pressure on employer budgets.
CFOs who treat pharmacy spend as a controllable expense, not a fixed line item, are in the strongest position to protect their organizations. This guide outlines the key drivers of pharmacy cost growth, how self-funded pharmacy benefits work, and the strategies CFOs can use to reduce spend without reducing access or benefit quality.
PolicySmart’s independent benchmarking gives CFOs the data needed to make these decisions with confidence.
Questions CFOs Are Asking
How can CFOs research and better understand options for pharmacy cost control?
How do pharmacy costs impact self-funded employer plans?
In a self-funded plan, the employer pays every pharmacy claim directly rather than through an insurance premium. Rising drug prices, increased utilization, and specialty medication trends flow straight into the company’s financials. This makes pharmacy spend one of the most volatile and rapidly growing components of a self-funded health plan and requires active oversight to prevent year-over-year cost escalation.
What drives higher pharmacy spend for employers?
Pharmacy spend increases are largely driven by specialty medications, high-cost chronic disease therapies, limited transparency in PBM pricing, and rising utilization among covered employees. Even when plan enrollment is stable, shifts toward higher-cost drug classes and complex treatment regimens can raise total pharmacy expenditures significantly.
How can CFOs reduce pharmacy costs without reducing benefits?
CFOs can lower pharmacy costs by tightening contract terms, ensuring accurate pricing structures, reviewing formularies, and implementing clinically appropriate utilization management. Tools such as step therapy, generic or biosimilar substitution, site-of-care optimization, and medication adherence support reduce unnecessary spend while preserving access and maintaining clinical effectiveness.
What should employers know about PBM transparency?
PBM arrangements often contain spread pricing, unclear rebate retention, and limited visibility into the true acquisition cost of drugs. Employers should understand how their PBM earns revenue, whether pricing is pass-through or spread-based, how rebates are handled, and what fees are embedded in claims. Transparency is essential for aligning PBM incentives with employer financial interests.
How does independent benchmarking help control pharmacy spend?
Benchmarking compares an employer’s pharmacy costs and utilization patterns to peer groups of similar size, industry, and risk profile. This reveals pricing inconsistencies, contract inefficiencies, and utilization outliers. With objective data, CFOs gain negotiation leverage, identify avoidable spend, and build a targeted strategy for cost control without reducing benefits or member access.
The Drivers Behind Rising Pharmacy Costs
Pharmacy inflation is being shaped by several structural and market trends that directly impact self-funded plans. Understanding these drivers allows CFOs to pinpoint where cost-control measures will generate real impact.
1. Specialty Medications
Specialty drugs are the single largest source of pharmacy cost growth. These include biologics, gene therapies, and complex injectables that treat chronic or rare conditions. Their utilization rates remain relatively low, but their per-member cost is substantial.
2. High-Cost Chronic Conditions
Chronic disease prevalence continues to rise. Conditions such as diabetes, autoimmune disorders, and behavioral health issues often require long-term drug therapy. Over time, this drives higher utilization and higher aggregate spend.
3. PBM Pricing Complexity
Traditional PBM models introduce layers of cost opacity. Spread pricing, unclear rebate structures, dispensing fees, and limited line-of-sight into acquisition costs all contribute to unpredictable pharmacy spending for employers.
4. Limited Oversight of Specialty Claims
Without ongoing review, high-cost claims can drift unchecked for multiple plan years. CFOs often do not see these patterns until a renewal meeting, long after corrective action could have been taken.
5. Employee Utilization Patterns
Higher prescription volumes per member, more frequent refills, and inconsistent medication adherence can increase both clinical risk and total spend.
How Self-Funded Pharmacy Benefits Work
A self-funded pharmacy benefit operates differently than a fully insured plan. Instead of paying fixed premiums, the employer assumes the financial responsibility for pharmacy claims.
The Structure
The employer partners with a pharmacy benefit manager or a third-party administrator to manage:
- Formularies
- Claims processing
- Rebates and discount arrangements
- Network access
- Clinical protocols
- Specialty medication programs
The employer pays claims as they are incurred. Stop-loss coverage may be layered on top to protect against catastrophic drug costs.
The Employer’s Role
In a self-funded environment, control comes with responsibility. Employers must actively monitor claim trends, evaluate utilization patterns, review pricing structures, and assess whether PBM terms align with actual pharmacy performance.
Because every claim hits the employer’s financials directly, transparency and ongoing oversight are essential.
How CFOs Can Reduce Pharmacy Costs Without Reducing Access
We know you want cost control, not benefit cuts. The following strategies preserve the member experience while reducing unnecessary spend.
1. Evaluate PBM Contract Structure
Hidden fees and pricing spreads can inflate costs without improving outcomes. CFOs should review terms for:
- Pass-through vs spread pricing
- Rebate transparency
- Dispensing fee structures
- Network pricing variability
- Specialty drug contract terms
The objective is alignment between employer cost and true drug acquisition value.
2. Implement Clinical and Utilization Management
Thoughtful oversight helps ensure medications are used appropriately and efficiently. Examples include:
- Step therapy when clinically suitable
- Prior authorization with clear criteria
- Care coordination for members with chronic conditions
- Medication adherence programs
These interventions improve outcomes and reduce avoidable spend.
3. Review Specialty Drug Strategy
Specialty drugs require a distinct, data-driven approach. CFOs should assess:
- Site-of-care optimization
- Alternative sourcing strategies where permitted
- Case management for long-term therapies
- Opportunities for negotiated pricing or outcomes-based models
Small adjustments in specialty drug management can generate measurable reductions.
4. Strengthen Employee Education
Members often do not know when a lower-cost, clinically equivalent option exists. Simple education on generics, biosimilars, or home delivery options can shift utilization patterns without limiting access.
5. Conduct Ongoing Pharmacy Data Audits
Quarterly or semi-annual reviews allow employers to identify anomalies, monitor drug mix, and verify that the plan is performing as expected. Regular audits also reveal inconsistencies in claims, formulary placement, or pricing.
How Independent Benchmarking Gives CFOs Clarity
Benchmarking is one of the most effective tools CFOs can use to assess pharmacy benefit performance. PolicySmart’s independent models compare employer pharmacy costs against peer groups of similar size, industry, and risk profile.
What Benchmarking Reveals
- Pricing patterns
- Utilization discrepancies
- Specialty drug concentration
- Contract inefficiencies
- Cost outliers that require corrective action
These insights provide leverage in negotiations with PBMs or TPAs and allow CFOs to see whether their plan performs within expected ranges.
Benchmarking turns pharmacy cost management into a data-backed discipline. CFOs gain a clear picture of avoidable spend, actionable opportunities, and a roadmap for long-term cost control.
Frequently Asked Questions
What drives pharmacy costs for self-funded employer groups?
Specialty drugs, chronic disease management, PBM pricing structures, and utilization patterns are the primary contributors.
Can employers reduce pharmacy costs without reducing benefits?
Yes. Contract optimization, clinical oversight, formulary review, and increased transparency often produce savings without restricting access or efficacy.
What should CFOs ask their PBM?
CFOs should request detail on pricing methodology, rebate retention, specialty pharmacy arrangements, formulary placement decisions, and any spread contained in the contract.
How often should pharmacy benefit performance be reviewed?
Quarterly reviews provide the most accurate visibility and allow adjustments before cost patterns become entrenched.
How does benchmarking improve pharmacy cost control?
Benchmarking shows where a plan stands relative to its peer group, identifies inefficiencies, and equips CFOs with data to drive negotiations and strategic decisions.
Does self-funding increase employer risk?
Self-funding increases responsibility and exposure to claims volatility, but stop-loss arrangements and structured oversight help mitigate these risks.